Deep Vein Thrombosis (DVT)

01Pathophysiology

DVT arises from the convergence of three pathological forces, collectively called Virchow's triad. Understanding this triad is critical because nearly every exam question about DVT risk factors traces back to one of these three mechanisms.

Venous stasis occurs when blood flow slows down in the deep veins, most commonly in the lower extremities. This is why prolonged immobilization (bed rest after hip replacement, long-haul flights, paralysis) is a classic risk factor. When blood pools, coagulation factors accumulate locally and are not cleared by normal flow, which promotes clot formation. This directly explains why the vignette patient is often described as being immobile for a prolonged period before symptom onset.

Endothelial injury refers to damage to the inner lining of the vein. Surgery, trauma, or indwelling catheters disrupt the normally antithrombotic endothelial surface, exposing subendothelial collagen and tissue factor. This triggers the coagulation cascade at the site of injury. Orthopedic surgeries (hip and knee replacement) are among the highest-risk procedures because they involve direct manipulation near large veins.

Hypercoagulability is any condition that shifts the hemostatic balance toward clot formation. This can be acquired (malignancy, pregnancy, oral contraceptives, nephrotic syndrome, antiphospholipid syndrome) or inherited (Factor V Leiden, Prothrombin G20210A mutation, deficiencies in Protein C, Protein S, or Antithrombin III). Malignancy deserves special emphasis: an unprovoked DVT in an older patient should prompt consideration of an occult cancer, and this is a commonly tested concept.

The thrombus usually begins in the venous valve cusps of the calf (distal DVT) where flow is most sluggish. It can then propagate proximally into the popliteal, femoral, and iliac veins. Proximal DVT (popliteal vein and above) carries the greatest risk of pulmonary embolism (PE), which is the most feared complication. This distinction between distal and proximal clot location is testable because management decisions differ based on it.

The swelling occurs because the clot obstructs venous outflow, raising hydrostatic pressure in the affected limb. The pain results from venous distension and inflammation of the vessel wall. Warmth and erythema are due to the inflammatory response surrounding the clot.

02Classification and Clinical Manifestation

Phlegmasia cerulea dolens and phlegmasia alba dolens are important complications of severe iliofemoral DVT that may appear in vignettes. Phlegmasia alba dolens presents with a pale, painful, swollen limb due to venous outflow obstruction. Phlegmasia cerulea dolens is the progression to a cyanotic, tense, massively edematous limb that can lead to venous gangrene and arterial compromise. This is a surgical emergency.

03Diagnostic Workup

The workup for DVT follows a structured algorithm that exam writers love to test, so understanding the decision tree is essential.

Step 1: Calculate the Wells Score. This is always the conceptual first step. The Wells criteria assign points for clinical features such as active cancer (+1), paralysis or recent immobilization (+1), bedridden > 3 days or major surgery within 12 weeks (+1), tenderness along the deep venous system (+1), entire leg swelling (+1), calf swelling > 3 cm compared to the other leg (+1), pitting edema (+1), collateral superficial veins (+1), and prior documented DVT (+1). A critical negative criterion is: an alternative diagnosis is at least as likely as DVT (-2). A score of 0 or less is low probability, 1 to 2 is moderate, and 3 or above is high.

Step 2: Branch based on probability.

For low probability: order a D-dimer. If the D-dimer is negative (<500 ng/mL by most assays), DVT is effectively ruled out and no further imaging is needed. If the D-dimer is positive, proceed to compression ultrasound. This is the most commonly tested pathway. Remember that D-dimer has excellent negative predictive value in low-risk patients but is useless for ruling in DVT because it is elevated in many other conditions.

For moderate to high probability: skip the D-dimer and go directly to compression ultrasonography. Ordering a D-dimer in a high-probability patient is a trap answer. A negative D-dimer does NOT rule out DVT when pre-test probability is high.

Step 3: Interpret the ultrasound. The hallmark finding is non-compressibility of the deep vein under direct probe pressure. A normal vein collapses completely when compressed. If the vein does not collapse, there is thrombus within it. Additional findings include visible intraluminal material and absence of color Doppler flow.

If the initial ultrasound is negative but clinical suspicion remains high, repeat the ultrasound in 5 to 7 days. Alternatively, proceed to CT venography or MR venography, particularly if iliac vein thrombosis is suspected (which ultrasound may miss).

Thrombophilia testing should be considered in patients with unprovoked DVT, recurrent DVT, DVT at a young age, or DVT in unusual sites (cerebral venous sinus, mesenteric, portal vein). However, testing should generally be deferred until after the acute anticoagulation period, as active anticoagulants interfere with results (e.g., heparin lowers antithrombin levels, warfarin lowers Protein C and S levels).

04Management and Treatment

Acute phase: The moment DVT is diagnosed (or even strongly suspected while awaiting confirmatory testing), anticoagulation should be initiated. Delay in treatment increases the risk of clot propagation and PE.

The current standard favors DOACs (rivaroxaban or apixaban) as first-line therapy for most patients because they do not require bridging with injectable heparin and have predictable pharmacokinetics without routine lab monitoring. Rivaroxaban is started at 15 mg twice daily for the first 21 days, then reduced to 20 mg once daily. Apixaban is started at 10 mg twice daily for the first 7 days, then reduced to 5 mg twice daily. Both must be taken with food (rivaroxaban especially, as absorption depends on it).

The LMWH-to-warfarin bridge is the traditional approach and remains important for patients who cannot take DOACs (e.g., severe renal impairment with CrCl <15 to 30 mL/min, antiphospholipid syndrome, mechanical heart valves). The key principle: warfarin must overlap with heparin for a minimum of 5 days, AND the INR must be at or above 2.0 for at least 24 hours before heparin is discontinued. This overlap is mandatory because warfarin initially creates a transient prothrombotic state by depleting Protein C (which has a shorter half-life than the procoagulant factors II, IX, and X). Stopping heparin too early can paradoxically worsen thrombosis. This bridging concept is heavily tested.

Unfractionated heparin is preferred over LMWH in patients with severe renal failure (because LMWH is renally cleared and accumulates), in patients who may need surgery soon (UFH has a short half-life of 1 to 2 hours and is reversible with protamine), and in very obese patients where LMWH dosing is uncertain.

Duration of anticoagulation depends on whether the DVT was provoked or unprovoked:

• Provoked DVT (identifiable, transient risk factor such as surgery, immobilization, oral contraceptives): 3 months of anticoagulation, then stop. The risk factor is gone, so the recurrence rate is low.

• Unprovoked DVT (no identifiable transient cause): minimum 3 months, then reassess the risk-benefit of indefinite anticoagulation. Many guidelines recommend extended therapy, especially in men and those with persistently elevated D-dimer after stopping treatment.

• Recurrent unprovoked DVT: indefinite anticoagulation.

• Cancer-associated DVT: anticoagulation continues for as long as the cancer is active. DOACs (edoxaban, rivaroxaban) or LMWH are preferred over warfarin due to superior efficacy in this population.

IVC filters are tested as a distractor. The only accepted indication is when anticoagulation is absolutely contraindicated (e.g., active, life-threatening hemorrhage). An IVC filter does not treat the clot. It merely prevents large emboli from reaching the lungs. Once the bleeding risk resolves, the patient should still receive anticoagulation, and the filter should be retrieved.

Contraindications to note:

• DOACs are contraindicated in antiphospholipid syndrome (increased thrombotic risk compared to warfarin) and in severe renal/hepatic impairment.

• Warfarin is teratogenic (Category X). In pregnant patients with DVT, use LMWH throughout pregnancy.

• Heparin-induced thrombocytopenia (HIT): if platelet count drops >50% during heparin therapy, discontinue all heparin products immediately and switch to a direct thrombin inhibitor (argatroban or bivalirudin). Do NOT switch to LMWH, as cross-reactivity is high.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common trap with DVT questions is ordering a D-dimer in a high-probability patient. When the clinical picture is strongly suggestive of DVT (e.g., unilateral swollen leg in a post-surgical patient with cancer), the next step is compression ultrasound, not D-dimer. A negative D-dimer does not reliably exclude DVT when pre-test probability is high, and a positive D-dimer adds nothing when you were already going to image. This tests your understanding of Bayesian reasoning and pre-test probability.

A second common trap involves the warfarin bridging question. Students frequently choose to stop heparin as soon as the INR reaches 2.0. The correct answer requires both conditions to be met: the INR must be at or above 2.0 for at least 24 hours AND at least 5 days of overlap with heparin. If either condition is unmet, continue the overlap.

Another heavily tested concept is the unprovoked DVT and occult malignancy connection. When a patient presents with an unprovoked DVT and has no obvious risk factors, an age-appropriate cancer screening should be considered. The question may ask what additional workup is indicated, and the answer involves screening (colonoscopy, mammography, CT of the chest/abdomen/pelvis depending on age and sex).

Watch for the HIT trap: a patient on heparin whose platelet count falls precipitously. The wrong answers will include switching to LMWH or simply reducing the heparin dose. The correct move is to discontinue all heparin immediately and start a direct thrombin inhibitor such as argatroban.

The pregnancy DVT question tests whether you know that warfarin crosses the placenta and is teratogenic. The correct answer in a pregnant patient is LMWH for the entire pregnancy. DOACs are also contraindicated in pregnancy due to insufficient safety data.

Finally, know that the IVC filter question usually appears as a tempting distractor. The answer is almost never "place an IVC filter" unless the question explicitly states the patient has an absolute contraindication to anticoagulation. IVC filters do not treat DVT, they only prevent large PE, and they come with their own complications (filter thrombosis, migration, caval perforation).

The core competency being tested across DVT questions is your ability to apply a structured diagnostic algorithm based on pre-test probability, choose the correct anticoagulant based on patient characteristics (renal function, pregnancy, cancer, antiphospholipid syndrome), and determine appropriate duration of therapy based on whether the event was provoked or unprovoked.